Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, discusses some of the key lung cancer updates presented at ASCO 2019, specifically mentioning treatments targeting KRAS and the drug ramucirumab. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.